Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales-Reference-Cited by-同舟云学术

Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales

Published:2022-01-19 Issue:1 Volume:60 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Blanchard Laurine S.¹^ORCID,Van Belkum Alex²,Dechaume Dominique²,Armstrong Thomas P.³,Emery Christopher L.⁴,Ying Yun X.⁵,Kresken Michael⁶,Pompilio Marion²,Halimi Diane²,Zambardi Gilles²

Affiliation:

1. bioMérieux SA, Marcy l’Etoile, France

2. bioMérieux, SA., La Balme-les-Grottes, France

3. bioMérieux Inc., Hazelwood, Missouri, USA

4. Indiana University School of Medicine, Indianapolis, Indiana, USA

5. Quest Diagnostics, Lewisville, Texas, USA

6. Antiinfectives Intelligence GmbH, Cologne, Germany

Abstract

Plazomicin (PLZ), brand name ZEMDRI (Cipla Therapeutics), is a novel aminoglycoside antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections including pyelonephritis.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01831-21

Reference27 articles.

1. Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections

2. Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology

3. A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales

4. Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance

5. Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights from financial analysis of the failure to commercialise plazomicin: Implications for the antibiotic investment ecosystem;Humanities and Social Sciences Communications;2024-07-20

2. In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug-resistant strains;The Journal of Antibiotics;2024-05-08

3. In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria—A Pilot Study in Bulgaria;Antibiotics;2024-01-15

4. Novel Antimicrobial Agents for Gram-Negative Pathogens;Antibiotics;2023-04-16